US20090114220A1 - Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber - Google Patents

Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber Download PDF

Info

Publication number
US20090114220A1
US20090114220A1 US12/296,983 US29698307A US2009114220A1 US 20090114220 A1 US20090114220 A1 US 20090114220A1 US 29698307 A US29698307 A US 29698307A US 2009114220 A1 US2009114220 A1 US 2009114220A1
Authority
US
United States
Prior art keywords
medicament
opening
magazine
removal
chamber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/296,983
Other languages
English (en)
Inventor
Herbert Wachtel
Johannes Geser
Burkhard P. Metzger
Michael Spallek
Michael Krueger
Hubert Kunze
Achim MOSER
Elmar Mock
Antonino Lanci
Andre Klopfenstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Assigned to BOEHRINGER INGELHEIM INTERNATIONL GMBH reassignment BOEHRINGER INGELHEIM INTERNATIONL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPALLEK, MICHAEL, KRUEGER, MICHAEL, METZGER, BURKHARD, KLOPFENSTEIN, ANDRE, LANCI, ANTONINO, MOCK, ELMAR, GESER, JOHANNES, MOSER, ACHIM, KUNZE, HUBERT, WACHTEL, HERBERT
Publication of US20090114220A1 publication Critical patent/US20090114220A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/002—Details of inhalators; Constructional features thereof with air flow regulating means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0038—Cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0043—Non-destructive separation of the package, e.g. peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Definitions

  • the invention relates to the field of medicament dispensing devices with a multi-dose magazine, particularly multi-dose powder inhalers, and relates to a medicament dispensing device according to the preamble of the independent claim. Also claimed is a medicament magazine for use in the medicament dispensing device, and a method of removing a medicament, particularly a powdered medicament.
  • Inhalers are known from the prior art in which a connection is made directly to a medicament chamber by means of a vacuum flow produced by inhaling (Venturi) and a powdered medicament contained therein is removed.
  • Venturi vacuum flow produced by inhaling
  • a powdered medicament is placed in wells arranged in a circle in an annular magazine.
  • a seal that closes off the wells is removed substantially in its entirety and a Venturi tube is arranged parallel to the magazine with the constriction above the well.
  • Attached to the Venturi tube is a longer turbulence chamber which is needed as the medicament is essentially removed from the well all in one go. With this device it is not possible to achieve accurate dosing of a medicament or adjustment to different dosages.
  • a medicament chamber is essentially divided into an entry and exit chamber which are joined together by a constricted passage.
  • a medicament is placed only in the entry chamber.
  • By piercing or introducing cannulas an air flow is produced through the medicament chamber from the entry chamber through the constriction into the exit chamber and out of the medicament chamber.
  • the entry and exit caber are each provided with two openings. In both specifications, the openings in the chambers are defined by the piercing.
  • WO 03/045483 a medicament chamber is pierced and a medicament contained therein is emptied out using an air flow produced by a compressed air source.
  • EP 0 547 429 discloses a cylindrical medicament magazine in which a fresh medicament chamber is brought into registry with a removal opening inside the apparatus by a screwing movement.
  • the air flow is subdivided: while one part empties the medicament chamber, the other part is passed through the apparatus and is combined with the medicament air current as an encircling air current.
  • an air flow is injected through a medicament chamber.
  • Individual medicament pouches are housed in an annular magazine. During use the pouches are pushed out of the magazine from behind, thereby severing a sealing film and are coupled with a removal mechanism. At the same time an air current is guided into and through the pouch at the maximum possible speed.
  • an individual channel is provided downstream of each pouch. With an additional bypass channel that circumvents the pouch and also opens into a mouthpiece, the total volume of air inhaled is increased and inhalation facilitates or guarantees a sufficient air current being present to transport the medicament to the user. Owing to the fact that some of the air current is deflected through the bypass channel, the air current through the pouch is reduced, so that the removal process is prolonged. The removal of the medicament can thus be spread over a somewhat longer period of time instead of all being removed at once.
  • the powder inhaler from WO 2005/002654 is relatively complicated in construction. A number of different parts are present, some of which move and have to be coordinated with one another. Moreover, the removal of the medicament is not triggered by an actual Venturi principle, but rather there is an intake current passing directly through the medicament pouches, and this can be weakened by a bypass flow.
  • the aim of the invention is therefore to provide a medicament dispensing device, a medicament magazine for use in such a medicament dispensing device and a method of removing a medicament form a medicament chamber in which the removal is based on the Venturi principle and the amount taken out can be metered accurately and reproducibly.
  • the invention is based on the principle known from U.S. Pat. No. 6,655,381, for example, of applying a Venturi-like vacuum flow to a medicament chamber and sucking the medicament contained therein out of the chamber by the vacuum and transporting it with the flow towards a mouthpiece. There, the medicament travels with the air current in the lungs of the user inhaling it.
  • a drive current is now produced in an air channel, which as a result of a constriction in the air channel produces a vacuum flow in this region.
  • the narrowest part of the air channel causing the reduced pressure flow is connected to a removal opening of a medicament chamber.
  • the removal opening is connected to a control opening, so that an emptying current is formed through the control opening via the removal opening and through the medicament chamber.
  • the emptying current is not connected to the drive current before entering the medicament chamber, but combines with the drive current after leaving the removal opening, so that a medicament carried along with the emptying current is transported with the drive current towards the mouthpiece.
  • the removal and control openings are preferably integrated directly in a medicament magazine. If the openings or the medicament magazine as a whole are produced by injection moulding from plastics, for example, these openings are very precisely defined, in a way which is not possible when an opening is produced by piercing, for example. By integrating the removal and control openings in the medicament magazine, these two openings are pre-defined and are fixed both before and after opening a medicament chamber.
  • control and removal openings form a major part of a throttle arrangement by which it is possible to control the emptying current and hence to vary the quantity of medicament removed per unit of time.
  • Other elements of the throttle arrangement with different effects may be the inner configuration of the medicament chamber itself, and the construction of the air channel connected to the removal opening, particularly its diameter.
  • the removal can be deliberately controlled, is precisely defined and above all reproducible.
  • a throttle effect and hence an emptying current can be deliberately selected on the basis of the accurately defined but variable elements such as the control opening, removal opening, inner configuration of the medicament chamber and can also easily be changed to other dosages, quantities and types of medicaments.
  • the inhaler may also have at least one bypass opening to assist the inhalation process, e.g. for children or people with weakened lungs.
  • This bypass opening serves to form a bypass flow which also leads to the mouthpiece and is preferably arranged downstream of a removal opening in the direction of the mouthpiece. However, it does not have any direct influence on a defined correlation between the vacuum flow, the removal opening and control opening.
  • a medicament chamber is preferably constructed so that at least some of the emptying current flows away over the medicament contained in the medicament chamber.
  • a suitable inner configuration of the medicament chamber it is also possible to influence the disaggregation and dispersion of a medicament.
  • additional turbulence can be introduced into an emptying current by means of a turbulence element, which is preferably formed by at least one part of the wall of the medicament chamber itself. This can increase the throttling effect or, if necessary, reduce it.
  • an additional vacuum flow can be produced, for example by means of a special configuration of a chamber wall or by means of a turbulence element. This is preferably arranged in a direct line between the control and removal openings, such that a medicament located on the floor of the medicament chamber is detached by this additional vacuum flow in the chamber. This can be achieved by, for example, the medicament chamber itself forming a kind of Venturi tube in all or part of the region between the control and removal openings.
  • a medicament magazine typically has a fill opening in addition to a control and removal opening.
  • This fill opening is preferably formed independently of the other two openings in the magazine. This has the advantage that the fill opening can be very large, to assist with the filling operation.
  • the fill opening is closed off, preferably sealed with a foil, after the introduction of a powder. If the medicament magazine is constructed as an annular magazine with a plurality of medicament chambers arranged in a circle therein, the control and removal openings of each chamber are spaced from one another, preferably on one side of the magazine, while the fill opening is arranged on the opposite side of the magazine. Thus, the opening of the control and removal openings is also independent of the removal of a sealing foil.
  • a medicament magazine has a plurality of medicament chambers and single doses contained therein.
  • the number is preferably in the range from 1 to 100 or up to 200 single doses, preferably in the range from 1-60, for example between 7-180 or 14-150, e.g. 30-120, 45-100, 30, 90, 60, 120.
  • the maximum number of single doses is preferably 60, for reasons of convenience and therapy.
  • An inhaler with a medicament magazine of this kind is very versatile in use. Besides the various possibilities of coordination and deliberate and very precise dosing possibilities, particularly their reproducibility, there is also the option of using the inhaler with a wide range of amounts and types of medicament. It is relatively simple to use a different medicament magazine, e.g. with a medicament chamber with a different, e.g. greater or smaller, capacity. If a removal opening is accurately defined by the medicament magazine itself, an adjacent (vacuum) opening in the Venturi suction tube may also be made larger without affecting the removal opening and hence the emptying current. As a result an inhaler can also be used with different medicament magazines, e.g. those with differently designed removal openings.
  • a medicament chamber may be very elongated, may have an angle, etc., and a control opening may be arranged accordingly at different locations in the magazine. This is possible as the control opening is not directly connected to the arrangement of the Venturi tube, and in particular, the drive current produced in the Venturi tube and the emptying current formed by the coupling of the vacuum flow to the magazine have a different origin.
  • a medicament chamber can be opened before the removal of the medicament by piercing, scraping or peeling off a sealing foil that closes off the medicament chamber.
  • a medicament chamber is designed accordingly, preferably such that the removal and control opening, which may also be referred to as control openings, are not affected by the opening mechanism. In particular, they are not affected by openings in the sealing foil itself or by an opening mechanism of the apparatus which produces such openings. This may be achieved for example by removing a sealing foil entirely from the control openings before the medicament is taken out, or by making an opening in a sealing foil so big that its effect on the control openings is negligible.
  • a medicament is emptied into a preliminary chamber, the preliminary chamber having a corresponding control and removal opening which is connected to a vacuum flow for removing the medicament.
  • a medicament may be sealed in its own medicament chamber with a sealing foil which is preferably opening by an opening means that may be installed in the chamber itself. In this embodiment this fill opening is arranged substantially on the same side as the control openings.
  • the preliminary chamber may be an integral part of the medicament chamber or the medicament magazine, or it may be an integral part formed on an air channel.
  • two medicament chambers are joined together through a common mouthpiece.
  • the individual medicament chambers of the two magazines are preferably arranged offset from one another.
  • it is also possible, when removing the medicament to open one chamber of each magazine and take one medicament from each. This is particularly advantageous if two medicaments have to be taken which cannot be stored together, or if every second time a double quantity of a medicament or medicament mixture has to be taken.
  • pharmaceutically permitted materials are preferably used.
  • the films used may be multi-layer films, for example, which are suitable as films for peeling or piercing or for scraping off.
  • Multi-layer films usually have a layer of PE, PP or PVC and an aluminium layer. Dependingon the particular requirement, a film is made more stable or tear-resistant, and this is pref done by incorporating a PET layer.
  • an outer layer of a film comprises the same material as an injected-moulded magazine, for example. In this way it is possible to seal or weld the different elements of a medicament magazine with the same materials. It is also possible to use sealing lacquer, e.g. heat-sealing lacquer. As a result, there are more possible material combinations for the individual elements.
  • a sealing lacquer is applied, for example, to a film and/or to a magazine that is to be closed off.
  • a foil prefferably has a layer of sealing lacquer directly.
  • the strength of the seal is preferably also optimally tailored to the use, so that, for example, a peelable film adheres directly but removably to an elements which is to be sealed.
  • W is a pharmacologically active substance and (for example) is selected from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors.
  • W is a pharmacologically active substance and (for example) is selected from among the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists and PI3-kinase inhibitors.
  • double or triple combinations of W may be combined and used in the apparatus accin. Combinations of W might be, for example:
  • the compounds used as betamimetics are preferably compounds selected from among albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharine, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, ritodrine, salmefamol, salmeterol, soterenol, sulphonterol, terbutaline, tiaramide, tolubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the anticholinergics used are preferably compounds selected from among the tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active constituents.
  • the above-mentioned salts may preferably contain the chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulphonate, while chloride, bromide, iodide, sulphate, methanesulphonate or p-toluenesulphonate are preferred as counter-ions.
  • the chlorides, bromides, iodides and methanesulphonates are particularly preferred.
  • X ⁇ denotes an anion with a single negative charge, preferably an anion selected from among the fluoride, chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, preferably an anion with a single negative charge, particularly preferably an anion selected from among the fluoride, chloride, bromide, methanesulphonate and p-toluenesulphonate, particularly preferably bromide, optionally in the form of the racemates, enantiomers or hydrates thereof.
  • those pharmaceutical combinations which contain the enantiomers of formula AC-1-ene
  • X ⁇ may have the above-mentioned meanings.
  • Other preferred anticholinergics are selected from the salts of formula AC-2
  • R denotes either methyl or ethyl and wherein X ⁇ may have the above-mentioned meanings.
  • the compound of formula AC-2 may also be present in the form of the free base AC-2-base.
  • corticosteroids it is preferable to use compounds selected from among beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR-106541, NS-126, ST-26 and
  • PDE4-inhibitors which may be used are preferably compounds selected from among enprofyllin, theophyllin, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofyllin, atizoram, D-4418, Bay-198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, CI-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the LTD4-antagonists used are preferably compounds selected from among montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078, VUF-K-8707, L-733321 and
  • EGFR-inhibitors which may be used are preferably compounds selected from among cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • the dopamine agonists used are preferably compounds selected from among bromocriptin, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexol, roxindol, ropinirol, talipexol, tergurid and viozan, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • H1-Antihistamines which may be used are preferably compounds selected from among epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, cexchlorpheniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclozine, optionally in the form of the racemates, enantiomers, diastereomers thereof and optionally in the form of the pharmacologically acceptable acid addition salts, solvates or hydrates thereof.
  • these acid addition salts are preferably selected from among the hydrochloride, hydrobromide, hydriodide, hydrosulphate, hydrophosphate, hydromethanesulphonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulphonate.
  • inhalable macromolecules may be used as disclosed in EP 1 003 478.
  • the compound may from the group of the derivatives of ergot alkaloids, triptanes, CGRP-inhibitors, phosphodiesterase-V inhibitors, optionally in the form of the racemates, enantiomers or diastereomers thereof, optionally in the form of the pharmacologically acceptable acid addition salts, solvates and/or hydrates thereof.
  • ergot alkaloid derivatives examples include dihydroergotamine, ergotamine.
  • substances suitable for inhalation include medicaments, medicament formulations and mixtures containing the above-mentioned active substances, and the salts and esters thereof and combinations of these active substances, salts and esters.
  • FIG. 1 shows a detail of a powder inhaler with the removal principle
  • FIG. 2 shows the removal principle, in simplified view
  • FIG. 3 shows a medicament magazine as an annular disc
  • FIG. 4 shows the medicament magazine with the medicament chamber open
  • FIG. 5 shows the entire medicament magazine
  • FIG. 6 shows a scale representation of the medicament magazine according to FIG. 3-5 .
  • FIG. 7 shows a medicament chamber for different opening mechanisms
  • FIG. 8 shows a double annular magazine with a combined air channel
  • FIG. 9 shows a double annular magazine with separate air channels
  • FIG. 10 shows a blister with internal structure and preliminary chamber as a medicament magazine
  • FIG. 11 shows two embodiments of a blister with internal structure.
  • FIG. 1 and FIG. 2 show the removal principle for a powder 6 containing a medicament and contained in a medicament chamber, such as may be used in a powder inhaler.
  • the medicament chamber is in the form of a cavity 7 in a plastics part preferably produced by injection moulding or thermoforming.
  • the medicament chamber has, on an upper side, a removal opening 2 which is connected directly to an air channel 4 .
  • the air channel is constructed as a Venturi tube.
  • the powder in the cavity is sucked out into the air channel 4 through the removal opening and together with the drive current 5 is carried towards the mouthpiece and the person using the inhaler.
  • the medicament chamber also has on its upper side, the same side as the removal opening, a control opening 3 through which air flows into and through the cavity and forms an emptying current. Some of this emptying current flows away over the powder 6 and can produce an additional Venturi effect with a turbulence element 15 located in the cavity between the turbulence element and the powder or the base of the cavity.
  • the turbulence element may also have structures, e.g. projections pointing into the medicament chamber, which intensify the turbulence of the air and powder.
  • the medicament chamber comprises a fill opening 13 on the bottom, opposite the top.
  • the fill opening 13 extends substantially over the entire lower surface of the cavity and is closed off with a sealing film 12 once the powder has been placed in the cavity.
  • the removal of the medicament can be adapted very sensitively and in versatile manner to all kinds of medicaments, dosages and user requirements. This can be done by varying and adapting the emptying flow, which is affected by several parameters: the diameter of the air channel above the removal opening, the dimensions of the removal opening, the configuration of the cavity, and the dimensions of the control opening.
  • the special configuration of the medicament magazine also allows easy adaptation to different amounts, compositions or consistencies of medicaments, e.g. by enlarging the cavity and/or changing the opening diameter.
  • the separate fill opening also allows this to be made as large as possible, so that a powder can be poured in very quickly and without having to be tailored to a special (small) fill opening. Also, because of the direct connection of a removal opening to the air channel and the vacuum flow prevailing therein, no powder is lost along lengthy passages or ducts.
  • the air channel 4 has additional sidestream or bypass openings which terminate in the air channel and are arranged offset downstream of a removal opening, towards the mouthpiece 9 . This reduces the suction force needed or creates crosscurrents in the air channel to assist with the dispersion of a powder contained therein.
  • FIG. 5 shows a multi-dose medicament magazine constructed as an annular magazine 1 , of the kind that may be used in a disc-type inhaler, for example.
  • the upper sealing film has been removed from five medicament chambers.
  • the plan view shows one removal and one control opening for each medicament chamber.
  • An annular magazine of this kind may be made in one piece by injection moulding, for example.
  • the upper sealing film is applied first. After filling, the cavity is closed off by means of the lower sealing film. Examples of preferred injection-moulding materials are PE, PP and PVC.
  • FIGS. 3 and 4 each show a diagonal view of a medicament chamber, shown cut away.
  • FIG. 3 shows a filled medicament chamber in which there is powder 6 in the cavity 7 .
  • the removal and control openings are covered by the upper sealing film 14 and are closed off thereby in airtight and watertight manner.
  • the lower fill opening one of which is preferably provided for each cavity, is closed off by a lower sealing film 12 .
  • FIG. 4 shows the same diagonal view of a medicament chamber after use.
  • the upper sealing film 14 has been removed.
  • the air flow 5 over the removal opening is guided through a constriction in the channel (cf. FIGS. 1 and 2 ), thereby producing a vacuum above this opening.
  • the dimensions of the removal and control opening are preferably such that the cavity is emptied as continuously as possible.
  • FIG. 6 shows a cross-section through a cavity, and a plan view of an annular magazine, drawn to scale, such as might be produced for a powder volume of about 10 mm 3 and 30 cavities, i.e. single doses, in an annular magazine.
  • the quantity of fill volume of a single dose may be varied relatively easily by changing the depth and/or length of the cavity.
  • the control opening can be arranged virtually anywhere in the magazine. It must not be adjacent to the removal opening on the same side of the annular magazine but it could, for example, be arranged on an inner diameter of the magazine.
  • FIG. 7 diagrammatically shows a section through the structure of a medicament chamber, as it might be designed in order to be opened by different opening mechanisms, such as peeling, scraping off or piercing, without affecting the control openings, i.e. the control and removal opening.
  • FIG. 7 shows a cavity 7 with the removal and control opening 2 , 3 spaced apart from each other.
  • the openings are set into a recess.
  • the height V and width B of the recess can be adapted to the particular opening mechanism. If the openings are exposed by peeling off a sealing film applied earlier, the height V of the recess is preferably zero and the width B (or area) of the recess corresponds to the width of the chamber.
  • a sealing film would be pierced and the size and shape of a removal opening and a control opening would be determined by the piercing tools. These are generally inexact and a throttled flow would not be defined and in particular would not be reproducible.
  • the recess depth V>0 and the width B is chosen to be greater than the chamber width.
  • piercing takes place independently of the actual removal and control opening.
  • the piercing tool is selected such that the foil is pierced over one or more areas which are greater than the area of the removal and control opening, such that any influence of the pierced opening(s) is negligibly small in relation to the control openings.
  • FIGS. 8 and 9 each show a section through a double medicament magazine, e.g. an annular magazine.
  • the magazine substantially corresponds to two annular magazines according to FIG. 3 which are arranged with their reverse sides, i.e. the sides containing the fill openings 13 , touching in mirror image and are attached to one another or only pressed together.
  • the two parts of the magazine are pushed together such that the individual medicament chambers 7 are not precisely opposite one another (the offset chamber is shown by dotted lines).
  • a multi-dose inhaler of for example 30 doses can be converted into a preferred 60-dose inhaler.
  • two air channels 4 , 4 ′ which belong to an upper and lower part of the magazine, open into the same mouthpiece 89 .
  • the mouthpiece and air channels are made in one piece. Because of the offset arrangement of the medicament chambers 7 (shown by dotted lines in FIG. 7 ) powder can only be taken from one chamber, even when the chambers are open.
  • the air channel 4 ′ which is not in use can be used for an additional air supply (bypass). However, it is also possible to arrange the chambers so that they are not offset from one another, so that two different medicaments, for example, can be taken from two chambers.
  • FIG. 9 shows a mouthpiece 99 which subdivides the two air channels 4 , 4 ′ so that no air can pass through a non-selected channel into the mouthpiece 99 .
  • the mouthpiece may be rotated for example from an upper part to a lower part of the magazine.
  • FIG. 10 shows another embodiment of the invention by reference to a medicament magazine which is constructed as a foil blister with an internal structure 101 .
  • This internal structure 106 has opening means, for example, in the form of piercing points or cutting edges by means of which a sealing foil that closes off a medicament chamber is opened by pressing the internal structure outwards.
  • the internal structure is preferably also constructed so that it gives a degree of stability to the medicament chamber. In this way, a powder contained therein is protected from mechanical influences from the outside or, in particular, when the chamber is opened. This is important for powdered medicament carriers for inhalers, as the inhaling or dosing of a compacted powder is no longer possible, or is no longer possible in a defined manner.
  • the foil blister 101 has, in the region of the actual medicament chamber, a preliminary chamber 105 .
  • the preliminary chamber 105 has a removal opening 2 and a control opening 3 .
  • the delivery of the powder 6 from the blister is preferably effected as follows: the contents of the blister are emptied or introduced into the preliminary chamber 105 with the aid of the internal structure, preferably directly during the action of loading an inhaler.
  • the preliminary chamber has a removal opening 2 which may be in the form of a through-bore and is connected to a Venturi suction tube 104 .
  • the maximum pressure difference is present at the through-bore, enabling the powder to be drawn out of the preliminary chamber 105 in metered amounts.
  • the air current 5 reaches its maximum speed, thus allowing efficient detachment (dispersion) of an active substance from the carrier.
  • a blister with an integrated preliminary chamber is produced, such that a medicament magazine with a fill opening, removal opening and control opening in turn forms a unit, while the openings are matched to one another, depending on the application.
  • a fresh preliminary chamber is provided for each inhalation.
  • a fresh suction tube or part of a suction tube is available for each removal is when the blister is formed with an integrated preliminary chamber and suction tube. Any medicament residues on the walls of the suction tube, which in particular occur directly in the region of the removal opening would thus not affect subsequent removals.
  • the preliminary chamber is in turn an integral part of the suction tube, but is independent of the foil blister and the actual medicament chamber.
  • FIG. 11 shows two examples on a larger scale.
  • the Figure shows one medicament chamber in the filled, unused state in each case.
  • Powder 6 is at least partly enclosed by the internal structure 3 and protected from external mechanical effects, but particularly from being compressed as the internal structure is pressed out of the medicament chamber.
  • the internal structures have piercing points or cutting edges 109 with which a sealing foil 107 is pierced or cut open and torn or cut away as the chambers are opened.
  • the internal structure may be connected to the blister, e.g. sealed on its reverse side with a film so as not to fall into the preliminary chamber depending on the position of the blister. However, if the preliminary chamber is an integral part of the blister or each individual medicament chamber located therein, this measure may not be necessary.
  • An internal structure of this kind may also serve as a turbulence element as well or in particular if it is freely positioned in the preliminary chamber.
  • the internal structure may also provide additional turbulence by means of an emptying current passing through the preliminary chamber and thus additionally contribute to the disaggregation and dispersion of the powder.
  • the internal structure is preferably very open in design, so that an air current can penetrate into and through the internal structure is possible from many sides. This contributes to emptying a medicament chamber as completely as possible and additional air turbulence.
  • the internal structure, preliminary chamber and suction tube are preferably formed by injection moulding a plastic. However, it is also possible to produce individual parts thereof by a thermoforming process or, in the case of internal structures, to stamp and form them from a foil, e.g. a metal foil.
US12/296,983 2006-04-13 2007-04-13 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber Abandoned US20090114220A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06405160.0 2006-04-13
EP06405160A EP1844806A1 (de) 2006-04-13 2006-04-13 Medikamenten-Ausgabevorrichtung, Medikamentenmagazin dafür, und Verfahren zur Entnahme eines Medikaments aus einer Medikamentenkammer
PCT/CH2007/000182 WO2007118343A1 (de) 2006-04-13 2007-04-13 Medikamenten-ausgabevorrichtung, medikamentenmagazin dafür und verfahren zur entnahme eines medikaments aus einer medikamentenkammer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2007/000182 A-371-Of-International WO2007118343A1 (de) 2006-04-13 2007-04-13 Medikamenten-ausgabevorrichtung, medikamentenmagazin dafür und verfahren zur entnahme eines medikaments aus einer medikamentenkammer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/482,359 Continuation US8561610B2 (en) 2006-04-13 2012-05-29 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber

Publications (1)

Publication Number Publication Date
US20090114220A1 true US20090114220A1 (en) 2009-05-07

Family

ID=36669868

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/296,983 Abandoned US20090114220A1 (en) 2006-04-13 2007-04-13 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber
US13/482,359 Active US8561610B2 (en) 2006-04-13 2012-05-29 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/482,359 Active US8561610B2 (en) 2006-04-13 2012-05-29 Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber

Country Status (5)

Country Link
US (2) US20090114220A1 (de)
EP (2) EP1844806A1 (de)
JP (1) JP2009533098A (de)
CA (1) CA2644263A1 (de)
WO (1) WO2007118343A1 (de)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070277820A1 (en) * 2003-10-27 2007-12-06 Timothy Crowder Blister packages and associated methods of fabricating dry powder drug containment systems
US20100078022A1 (en) * 2008-09-26 2010-04-01 Rachel Striebig Inhalers with airway disks having discrete airway channels and related disks and methods
US20110036348A1 (en) * 2007-12-20 2011-02-17 Orest Lastow Device and method for deaggregating powder
USD635246S1 (en) 2010-03-26 2011-03-29 Oriel Therapeutics, Inc. Dose disk for dry powder inhalers
USD641076S1 (en) 2010-03-26 2011-07-05 Oriel Therapeutics, Inc. Dry powder inhaler
US20110162648A1 (en) * 2008-09-26 2011-07-07 Ruckdeschel Thomas W Inhaler mechanisms with radially biased piercers and related methods
US20110174306A1 (en) * 2008-09-30 2011-07-21 David Harris Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods
US20110186047A1 (en) * 2008-10-01 2011-08-04 Scott Alexander Lewis Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods
US8381721B2 (en) 2008-09-26 2013-02-26 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and related devices and methods
WO2013184951A3 (en) * 2012-06-06 2014-03-27 Aerodesigns, Inc. Aerosol dispenser with replaceable cartridge
US20140216454A1 (en) * 2007-07-06 2014-08-07 Manta Devices, Llc Dose delivery device for inhalation
US8919341B2 (en) 2008-12-03 2014-12-30 Boehringer Ingelheim International Gmbh Inhaler
US9119924B2 (en) 2009-03-17 2015-09-01 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
EP2928315A2 (de) * 2012-12-06 2015-10-14 AeroDesigns, Inc Aerosolspender mit essbarer kartusche
US9211383B2 (en) 2009-07-01 2015-12-15 Astrazeneca Ab Dispenser and method for entraining powder in an airflow
WO2019222836A1 (en) * 2018-05-21 2019-11-28 Willinsky Michael An inhalation vaporizer with an aliquot dispenser for delivering metered doses
US10632268B2 (en) 2005-07-20 2020-04-28 Manta Devices, Llc Inhalation device
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP1894591B1 (de) 2002-03-20 2013-06-26 MannKind Corporation Kartusche für eine Inhalationsvorrichtung
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
ES2543007T3 (es) 2004-08-23 2015-08-13 Mannkind Corporation Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos
IN2014DN09128A (de) 2005-09-14 2015-07-10 Mannkind Corp
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
RU2492877C2 (ru) 2008-02-12 2013-09-20 Астразенека Аб Ингалятор, содержащий основание, имеющее большое количество содержащих лекарственное средство герметичных полостей
JP2011511690A (ja) * 2008-02-12 2011-04-14 アストラゼネカ・アクチエボラーグ 薬剤を収容する少なくとも１個の封止キャビティを有する基部を備える吸入器
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP3281663B8 (de) 2008-06-13 2022-09-21 MannKind Corporation Atemluftbetriebener trockenpulverinhalator zur verabreichung von medikamenten
WO2009155581A1 (en) 2008-06-20 2009-12-23 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
GB2474697A (en) * 2009-10-23 2011-04-27 Cambridge Design Res Llp A medicament container for an inhaler comprising a base with a plurality of cavities and a foil lid sealed to at least two surfaces of the base
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
JP6385673B2 (ja) 2010-06-21 2018-09-05 マンカインド コーポレイション 乾燥粉末薬物送達システム
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
MX354163B (es) 2012-07-12 2018-02-15 Mannkind Corp Sistemas y métodos de suministro de fármaco en polvo seco.
EP2911690A1 (de) 2012-10-26 2015-09-02 MannKind Corporation Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
KR102391750B1 (ko) 2013-03-15 2022-04-28 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US9019329B2 (en) * 2013-07-25 2015-04-28 Xerox Corporation Systems for dampening fluid removal, vapor control and recovery for ink-based digital printing
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3159030A1 (de) * 2015-10-23 2017-04-26 Presspart Manufacturing Ltd. Trockenpulverinhalator
EP3687608A4 (de) 2017-09-28 2021-06-16 Iconovo AB Trockenpulverinhalator mit mitteln zur verbesserung der dispersion
CA3227858A1 (en) 2021-09-29 2023-04-06 Norton (Waterford) Limited Dry powder medicament inhaler
WO2024033662A1 (en) * 2022-08-12 2024-02-15 Cambridge Healthcare Innovations Limited Negative pressure amplification apparatus and inhaler

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476093A (en) * 1992-02-14 1995-12-19 Huhtamaki Oy Device for more effective pulverization of a powdered inhalation medicament
US5715810A (en) * 1991-07-25 1998-02-10 Sepracor Inc. Inhalation devices
US6655381B2 (en) * 2000-06-23 2003-12-02 Ivax Corporation Pre-metered dose magazine for breath-actuated dry powder inhaler
US7318436B2 (en) * 2000-05-10 2008-01-15 Innovative Devices, Llc Medicament container with same side airflow inlet and outlet and method of use
US7464706B2 (en) * 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027234D0 (en) * 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
DE4211475A1 (de) 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
WO1994006497A1 (en) * 1992-09-11 1994-03-31 Glaxo Group Limited Inhalation device
US5483954A (en) * 1994-06-10 1996-01-16 Mecikalski; Mark B. Inhaler and medicated package
GB2340758A (en) * 1998-08-21 2000-03-01 Bespak Plc Drug dispensing system
AU779693B2 (en) 1999-07-23 2005-02-03 Mannkind Corporation Unit dose capsules and dry powder inhaler
US6810872B1 (en) * 1999-12-10 2004-11-02 Unisia Jecs Corporation Inhalant medicator
GB0113881D0 (en) 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system
GB0128148D0 (en) * 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
GB0427028D0 (en) * 2004-12-09 2005-01-12 Cambridge Consultants Dry powder inhalers
WO2007018568A1 (en) * 2005-07-20 2007-02-15 Manta Devices, Llc Inhalation device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5715810A (en) * 1991-07-25 1998-02-10 Sepracor Inc. Inhalation devices
US5476093A (en) * 1992-02-14 1995-12-19 Huhtamaki Oy Device for more effective pulverization of a powdered inhalation medicament
US7464706B2 (en) * 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7318436B2 (en) * 2000-05-10 2008-01-15 Innovative Devices, Llc Medicament container with same side airflow inlet and outlet and method of use
US6655381B2 (en) * 2000-06-23 2003-12-02 Ivax Corporation Pre-metered dose magazine for breath-actuated dry powder inhaler

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070277820A1 (en) * 2003-10-27 2007-12-06 Timothy Crowder Blister packages and associated methods of fabricating dry powder drug containment systems
US10632268B2 (en) 2005-07-20 2020-04-28 Manta Devices, Llc Inhalation device
US11672927B2 (en) 2005-07-20 2023-06-13 Manta Devices, Llc Inhalation device
US11491287B2 (en) 2005-07-20 2022-11-08 Manta Devices, Llc Inhalation device
US9919115B2 (en) * 2007-07-06 2018-03-20 Manta Devices, Llc Dose delivery device for inhalation with first and second portions to open a dose chamber
US11224704B2 (en) 2007-07-06 2022-01-18 Manta Devices, Llc Dose delivery device for inhalation
US20140216454A1 (en) * 2007-07-06 2014-08-07 Manta Devices, Llc Dose delivery device for inhalation
US8479729B2 (en) 2007-12-20 2013-07-09 Astrazeneca Ab Device and method for deaggregating powder
US20110036348A1 (en) * 2007-12-20 2011-02-17 Orest Lastow Device and method for deaggregating powder
US20110226243A1 (en) * 2007-12-20 2011-09-22 Orest Lastow Device and method for deaggregating powder 854
US8151793B2 (en) 2007-12-20 2012-04-10 Astrazeneca Ab Device and method for deaggregating powder
US9283337B2 (en) 2007-12-20 2016-03-15 Astrazeneca Ab Dispenser and method for entraining powder in an airflow
US8578933B2 (en) 2007-12-20 2013-11-12 Astrazeneca Ab Entraining powder in an airflow
US9597465B2 (en) 2008-09-26 2017-03-21 Oriel Therapeutics, Inc. Methods of operating and fabricating inhalers with airway disks having discrete airway channels
US8985103B2 (en) 2008-09-26 2015-03-24 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members
US10493222B2 (en) 2008-09-26 2019-12-03 Oriel Therapeutics, Inc. Dry powder dose container assemblies and related inhalers
US8550071B2 (en) 2008-09-26 2013-10-08 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US8671938B2 (en) 2008-09-26 2014-03-18 Oriel Therapeutics, Inc. Inhalers with airway disks having discrete airway channels and related disks and methods
US20100078022A1 (en) * 2008-09-26 2010-04-01 Rachel Striebig Inhalers with airway disks having discrete airway channels and related disks and methods
US9795749B2 (en) 2008-09-26 2017-10-24 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and methods of operating same
US8381721B2 (en) 2008-09-26 2013-02-26 Oriel Therapeutics, Inc. Dry powder inhalers with dual piercing members and related devices and methods
US8887722B2 (en) 2008-09-26 2014-11-18 Oriel Therapeutics, Inc. Inhaler mechanisms with radially biased piercers and related methods
US20110162648A1 (en) * 2008-09-26 2011-07-07 Ruckdeschel Thomas W Inhaler mechanisms with radially biased piercers and related methods
US9050427B2 (en) 2008-09-30 2015-06-09 Oriel Therapeutics, Inc. Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods
US20110174306A1 (en) * 2008-09-30 2011-07-21 David Harris Dry Powder Inhalers with Multi-Facet Surface Deagglomeration Chambers and Related Devices and Methods
US20110186047A1 (en) * 2008-10-01 2011-08-04 Scott Alexander Lewis Dry Powder Inhalers with Rotating Piercing Mechanisms and Related Devices and Methods
US8646446B2 (en) 2008-10-01 2014-02-11 Oriel Therapeutics, Inc. Dry powder inhalers with rotating piercing mechanisms and related devices and methods
US8919341B2 (en) 2008-12-03 2014-12-30 Boehringer Ingelheim International Gmbh Inhaler
US9119924B2 (en) 2009-03-17 2015-09-01 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US9211383B2 (en) 2009-07-01 2015-12-15 Astrazeneca Ab Dispenser and method for entraining powder in an airflow
USD635246S1 (en) 2010-03-26 2011-03-29 Oriel Therapeutics, Inc. Dose disk for dry powder inhalers
USD745660S1 (en) 2010-03-26 2015-12-15 Oriel Therapeutics, Inc. Dry powder inhaler
USD711528S1 (en) 2010-03-26 2014-08-19 Oriel Therapeutics, Inc. Dry powder inhaler
USD684684S1 (en) 2010-03-26 2013-06-18 Oriel Therapeutics, Inc. Dry powder inhaler
USD641076S1 (en) 2010-03-26 2011-07-05 Oriel Therapeutics, Inc. Dry powder inhaler
USD685461S1 (en) 2010-03-26 2013-07-02 Oriel Therapeutics, Inc. Dose disk for a dry powder inhaler
US9845187B2 (en) 2012-06-06 2017-12-19 Aerodesigns, Inc. Aerosol dispenser with replaceable cartridge
WO2013184951A3 (en) * 2012-06-06 2014-03-27 Aerodesigns, Inc. Aerosol dispenser with replaceable cartridge
EP2928315A2 (de) * 2012-12-06 2015-10-14 AeroDesigns, Inc Aerosolspender mit essbarer kartusche
US11147936B2 (en) 2014-05-02 2021-10-19 Manta Devices, Llc Dose delivery device with cover connected to dose chamber seal
WO2019222836A1 (en) * 2018-05-21 2019-11-28 Willinsky Michael An inhalation vaporizer with an aliquot dispenser for delivering metered doses

Also Published As

Publication number Publication date
EP2004263A1 (de) 2008-12-24
EP1844806A1 (de) 2007-10-17
JP2009533098A (ja) 2009-09-17
CA2644263A1 (en) 2007-10-25
US8561610B2 (en) 2013-10-22
EP2004263B1 (de) 2014-01-29
US20120247465A1 (en) 2012-10-04
WO2007118343A1 (de) 2007-10-25

Similar Documents

Publication Publication Date Title
US8561610B2 (en) Medicament dispensing device, medicament magazine therefor and method of removing a medicament from a medicament chamber
US8267082B2 (en) Medicaments magazine for an inhaler, and a multi-dose powder inhaler
US7870856B2 (en) Inhaler
US9259540B2 (en) Nozzle and inhaler and method for producing a nozzle
US8746244B2 (en) Powder inhaler
US8733341B2 (en) Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
US8950396B2 (en) Dispensing device (CAT)
US9604017B2 (en) Needle for piercing a powder capsule for inhalation
US8528548B2 (en) Inhaler
US20110203586A1 (en) Powder Inhalers
US20090235929A1 (en) Powder inhalers
US8205613B2 (en) Piston dosing pump
US8281784B2 (en) Mouthpiece for an inhaler
US20100252032A1 (en) Inhaler
US20100275917A1 (en) Powder inhaler
US9533112B2 (en) Inhaler
US8286632B2 (en) Dispensing device
US20100059051A1 (en) Inhaler
US8602024B2 (en) Medicaments magazine, and a device and method for opening it; multi-dose powder inhaler
US8944054B2 (en) Medicine dispensation device
US20100327476A1 (en) Method and device for filling capsules
US20070221535A1 (en) Package for multiple dose inhalators having optimised emptying properties

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM INTERNATIONL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WACHTEL, HERBERT;GESER, JOHANNES;METZGER, BURKHARD;AND OTHERS;REEL/FRAME:022037/0816;SIGNING DATES FROM 20081031 TO 20081201

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION